From lab to clinic: the rise of Radio-DARPins in oncology
Drug Target Review
JULY 30, 2025
Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. Although RLT has already demonstrated success in certain haematological and prostate cancers, its application in solid tumours has historically faced a number of biological and technical challenges – from limited tissue penetration to off-target toxicity, particularly in organs like the kidneys.
Let's personalize your content